Navigation Links
Sex lives of patients are negatively affected by RA and SLE
Date:6/18/2010

matode (ANDAR), Paris, France and lead author of the French study. "What is worrying is that patients are often reluctant to speak to their doctor about this, which means they continue to suffer both physically and emotionally. We encourage doctors to initiate conversations with patients to offer support to those that may benefit."

The results of a separate study of 125 Brazilian women, all of whom were receiving treatment for SLE (mean age 32 years, 52.8% of SLE group married vs 27.5% of controls) showed statistically significant differences between sexual activities reported between patients with SLE and healthy controls including: absence of sexual activity (31.2% vs. 12.5% respectively (p=<0.05)), absence of arousal during sex (58.4% vs. 17.5% (p=<0.05)) and absence of orgasm (67.2% vs. 22.5% respectively (p=<0.05)).

Study designs and key statistics In the French study, 1,271 (38%) of patients responded to a pre-tested questionnaire distributed to all members of ANDAR, a national RA patient association. The research team collated information on current treatments with 98% of patients receiving treatment at the time of survey, 41% of whom were receiving biological therapies. Twenty percent of patients scored ≤2 in the Health Assessment Questionnaire*, indicating a high impact on health was associated with the condition).

In the Brazilian study, 165 women with SLE registered at the Rheumatology Unit of the State University of Campinas, Brazil, were asked to fill out the Short Personal Experiences Questionnaire (SpeQ) anonymously. Responses were compared against those from 40 healthy women, matched by age, education and socio-economic status. Seventy-five percent of women approached completed the questionnaire, with a mean age of 32 years for the SLE group and 30 years for the control group. Fifty-two percent of patients with SLE reported having current sexual partners vs. 92.5% of controls (p= < 0.05) with 32.8% of SLE patients r
'/>"/>

Contact: Caroline Butt
eularpressoffice@uk.cohnwolfe.com
44-778-927-0392
European League Against Rheumatism
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Sex lives of patients are negatively affected by rheumatoid arthritis and SLE
2. Drug That Stops Bleeding Could Save Lives
3. Heart pumps save lives
4. Videoconferencing with family members enriches the lives of nursing home residents
5. Updated HIV therapy guidelines would reduce risk of transmission, save lives, billions in costs
6. Mountain Retreat for Women Whose Lives Have Been Touched by Cancer
7. Kidney removal does not prolong the lives of elderly patients with localized kidney cancer
8. Dental Practice Marketing Specialist Publishes 1st Article for LIVESTRONG.COM
9. New Partnership Aims to Stop Phone Use While Driving and Save Lives
10. Canadians Leading Longer, Healthier Lives Than Americans
11. 1 in 4 Chronically Ill Elderly Lives Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Heritage Woods of Dwight ... affordable assisted living community, is hosting a Quality Home Health ... 2 p.m. on Tuesday, May 28. , The community, which ... older adults of all incomes, including those on Medicaid, who ... program is open to the public. There is no ...
(Date:5/21/2013)... the George Washington (GW) University School of ... the launch of the Avance Center for ... between SPHHS, the Maryland Multicultural Youth Centers, ... This university-community partnership aims to address public ... through research, mutual capacity building and prevention ...
(Date:5/21/2013)... 2013 Patients of Dr. Michael Shenk and ... teeth due to gum disease and would like permanent tooth ... treatment with laser gum surgery. Gum disease must ... success rate out of all tooth replacement options. , ... new procedure cleared by the Food and Drug Administration (FDA) ...
(Date:5/21/2013)... LEAWOOD, Kan. Primary care practice transformation on ... health care reform efforts aimed at achieving better ... Amid emerging evidence that transformation toward the patient-centered ... today,s health care environment, the U.S. Department of ... and Quality funded 14 studies to learn more ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... Mass., Jan. 3 Boston Scientific,Corporation (NYSE: ... upcoming JP,Morgan Health Care Conference, in San Francisco., ... a 25-minute,presentation on Wednesday, January 9th, beginning at ... Executive Vice President,and Chief Financial Officer will join ...
... new retrospective study on the effects of N-acetylcysteine ... caused by acetaminophen poisoning has found that the ... higher incidence of liver recovery, and better survival ... issue of Liver Transplantation, a journal by John ...
... no raised risk to heart , , THURSDAY, Jan. 3 ... but controversial treatment for prostate cancer reduces long-term death ... as some specialists had feared. , In patients ... testosterone-lowering drugs and radiation therapy appeared to lower the ...
... ... issued, PARAMUS, N.J., Jan. ... forcing the conversion of its Series A,Convertible Preferred Stock. At 5:00 p.m., ... of common stock. All of the issued and outstanding shares of Series,A ...
... Insulet Corporation,(Nasdaq: PODD ), the manufacturer and ... that Duane DeSisto, Chief Executive,Officer, will participate in ... scheduled to present an overview of the Company,at ... 2008 at The Westin St.,Francis Hotel in San ...
... is a former Officer of Aetna, Inc., ... HSKA ) today announced that Ms. Louise McCormick ... http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ), "We pride ourselves on ... Board consisting of high quality, independent Directors,is critical ...
Cached Medicine News:Health News:Boston Scientific to Participate in JP Morgan Health Care Conference 2Health News:Treatment with NAC is associated with better outcomes for children with liver failure 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 2Health News:Combo Therapy Cuts Prostate Cancer Death Rates 3Health News:Smart Balance Announces Conversion of Convertible Preferred Stock 2Health News:Louise McCormick Joins Heska's Board of Directors 2Health News:Louise McCormick Joins Heska's Board of Directors 3
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: ... the design, manufacture and sale of medical devices and in ... Dr. Jun Ma , President and CEO ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. The Company,s presentation is scheduled to ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
... The CritSpin whisper quiet, compact system ... clinic anywhere fast, accurate and cost effective ... Digital Reader, the CritSpin System offers a ... spin, complete cell packing - Meets NCCLS ...
... light over one smooth pulse duration, rather ... damage skin) that other technologies use. Palomar's ... water supply through the StarLux handpiece, down ... to as low as 4 degrees C. ...
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
Used for stenting the urethra during hypospadias or epispadias repair and to promote postoperative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: